PP
ACAD icon

PDT Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

PDT Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,327
Closed -$205K – 680
2025
Q1 		$205K Buy
12,327
+1
+0% +$18 0.01% 672
2024
Q4 		$226K Sell
12,326
-892
-7% -$14.4K 0.02% 635
2024
Q3 		$203K Buy
+13,218
New +$221K 0.02% 658
2024
Q1 		– Sell
-13,599
Closed -$426K – 617
2023
Q4 		$426K Sell
13,599
-27,160
-67% -$649K 0.05% 426
2023
Q3 		$849K Sell
40,759
-56,746
-58% -$1.54M 0.11% 323
2023
Q2 		$2.34M Sell
97,505
-69,490
-42% -$1.54M 0.32% 94
2023
Q1 		$3.14M Buy
166,995
+137,309
+463% +$2.62M 0.43% 63
2022
Q4 		$473K Buy
29,686
+6,400
+27% +$100K 0.08% 401
2022
Q3 		$381K Sell
23,286
-63,722
-73% -$1.03M 0.06% 513
2022
Q2 		$1.23M Sell
87,008
-157,817
-64% -$2.95M 0.11% 321
2022
Q1 		$5.93M Buy
244,825
+55,697
+29% +$1.35M 0.51% 17
2021
Q4 		$4.41M Sell
189,128
-34,002
-15% -$684K 0.34% 77
2021
Q3 		$3.71M Buy
223,130
+173,130
+346% +$3.34M 0.27% 175
2021
Q2 		$1.22M Buy
+50,000
New +$1.13M 0.08% 337
2018
Q4 		– Sell
-512,358
Closed -$10.6M – 458
2018
Q3 		$10.6M Sell
512,358
-169,142
-25% -$2.66M 0.44% 62
2018
Q2 		$10.4M Buy
681,500
+70,800
+12% +$1.26M 0.4% 79
2018
Q1 		$13.7M Buy
+610,700
New +$16.9M 0.46% 66
2016
Q1 		– Sell
-120,771
Closed -$4.3M – 557
2015
Q4 		$4.3M Buy
120,771
+69,340
+135% +$2.44M 0.59% 28
2015
Q3 		$1.7M Sell
51,431
-100,421
-66% -$4.18M 0.04% 520
2015
Q2 		$6.36M Buy
+151,852
New +$5.88M 0.17% 143

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

PDT Partners's ACAD Position: Q2 2025 in Review

PDT Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 12,327 shares — an estimated $205K sold.

PDT Partners first reported a position in ACAD in Q2 2015 and held it in 20 quarters. The position peaked at $13.7M in Q1 2018. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • PDT Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • PDT Partners sold 12,327 Acadia Pharmaceuticals shares in Q2 2025, an estimated $205K.
  • PDT Partners first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 20 quarters.
  • PDT Partners's Acadia Pharmaceuticals position peaked at $13.7M in Q1 2018.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on PDT Partners's 13F filing for Q2 2025, filed 14 Aug 2025.